Exploring Cancer Biomarker Testing (CNE)

Precision Medicine for Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Exploring Cancer Biomarker Testing, participants will learn about large panel biomarker tests, which test for dozens or hundreds of genomic variants and other biomarkers that may be driving cancer growth and may be targetable with treatment.  Learn about benefits, limitations, and challenges of using large panel biomarker tests using the five parts of this module: an animated video providing overview information; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

To claim credit, follow the steps in the learning path.

CNE Information and Disclosures

Original Release:  December 20, 2016
Renewal Date: May 25, 2023
Expiration Date: May 16, 2025

Target Audience
This activity is designed to meet the educational needs of practicing nurses and advanced practice nurses who provide oncology care.

Learning Outcome
Recognize the clinical utility of information gained from biomarker testing in cancer patients

CNE Approval Statement
The Jackson Laboratory is co-providing this continuing nursing education activity with the American Medical Association and Scripps Health. This nursing continuing professional development activity was approved by the Northeast Multistate Division Education Unit, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 4 out of 5 questions correctly and 4) complete the evaluation.  

Nurses are eligible for a maximum of .50 contact hours upon the completion of this activity.

Contributors

• Emily Edelman, MS, CGC - The Jackson Laboratory
• Therese Ingram, MA - The Jackson Laboratory
• Lindsey Kelley, MPH, MS, CGC - The Jackson Laboratory
• Kalisi Logan, MS, CGC - The Jackson Laboratory
• Laura Nicholson, MD, PhD - Scripps Health
• Kate Reed, MPH, ScM, CGC - The Jackson Laboratory
• Jens Rueter, MD - The Jackson Laboratory
• Linda Steinmark, MS, CGC - The Jackson Laboratory
• Christine M. Walko, PharmD, BCOP, FCCP - Moffitt Cancer Center
• Janet K. Williams, PhD, RN, FAAN - University of Iowa

Conflict of Interest Disclosure
This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest. Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course. All educational material has been peer-reviewed by external reviewers to assess for bias.

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program:

Kalisi Logan is an advisor for Igentify. Janet Williams is a stockholder in Pfizer. Ms. Logan's and Dr. Williams' contributions were peer reviewed by non-conflicted team members and modified as needed according to the results for the review to remove any identified commercial bias. 

References

Chakravarty, D., Johnson, A., Sklar, J., et al. (2022). Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol, 40(11), 1231-1258.

Chan, H. T., Chin, Y. M., & Low, S. K. (2022). Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. Cancers (Basel), 14(13).

Bristol-Myer Squibbs. (2023). Opdivo (nivolumab) v. 2/23 [package insert]. Retrieved 5/8/23.

Cristescu, R., Aurora-Garg, D., Albright, A., Xu, et al. (2022). Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer, 10(1).

El-Deiry, W. S., Goldberg, R. M., Lenz, H. J., et al. (2019). The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin, 69(4), 305-343.

Freedman, A. N., Klabunde, C. N., Wiant, K., et al. (2018). Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precis Oncol, 2.

Frugtniet, B., Morgan, S., Murray, A., et al. (2022). The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. BJOG, 129(3), 433-442.

George, A., & Turnbull, C. (2021). Tumor-only sequencing for oncology management: Germline-focused analysis and implications. Genes Chromosomes Cancer, 60(5), 352-357.

Li, M. M., Datto, M., Duncavage, et al. (2017). Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn, 19(1), 4-23.

Mandelker, D., Donoghue, M., Talukdar, S., et al. (2019). Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol, 30(8), 1221-1231.

Marabelle, A., Fakih, M., Lopez, J., et al. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol, 21(10), 1353-1365.

Marrone, M., Filipski, K. K., Gillanders, et al. (2014). Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. PLoS Curr, 6.

Morganti, S., Tarantino, P., Ferraro, E., et al. (2019). Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol, 133, 171-182.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer, v1.2023. Retrieved 4/26/23.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, v2.2022. Retrieved 4/27/23.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, v1.2023. Retrieved 4/27/23.

National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms, v.2.2023. Retrieved 5/8/23

Pinheiro, A. P. M., Pocock, R. H., Switchenko, J. M., Dixon, M. D., Shaib, W. L., Ramalingam, S. S., & Pentz, R. D. (2017). Discussing molecular testing in oncology care: Comparing patient and physician information preferences. Cancer, 123(9.

Tang, Y., Hu, X., Wu, K., & Li, X. (2022). Immune landscape and immunotherapy for penile cancer. Front Immunol, 13, 1055235.

Hardware/Software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.

Disclaimer 
All information in Precision Medicine for Your Practice is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Precision Medicine for Your Practice. Reliance on any information in Precision Medicine for Your Practice is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Precision Medicine for Your Practice.